Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTR008 vs Octreotide LAR in GEP-NETs
NCT05459844Phase 3Active, not recruiting
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Aug 2022
- Primary completion
- Jun 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET) (2 arms), sponsored by Sinotau Pharmaceutical Group. Primary endpoint: Progression Free Survival at 34 months. Started Aug 2022; status: active, not recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT05459844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05459844.